Source comparison
Sourcing Differences — Research-Grade vs Pharmaceutical-Grade Material
Research-grade PT-141 is supplied as lyophilised powder in multi-dose vials, requiring reconstitution with bacteriostatic water before subcutaneous injection. The peptide is stable at −20°C in powder form for 24–36 months, but once reconstituted, it must be re
This comparison does not assign a generated winner or score.
- Research-grade PT-141 is supplied as lyophilised powder in multi-dose vials, requiring reconstitution with bacteriostatic water before subcutaneous injection. The peptide is stable at −20°C in powder form for 24–36 months, but once reconstituted, it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible aggregation of the cyclic peptide structure. The MC4R binding affinity degrades, and potency is lost without any visible change to the solution.
- Pharmaceutical-grade bremelanotide (Vyleesi) is supplied as a pre-filled, single-use autoinjector containing 1.75mg bremelanotide in a sterile, buffered solution. The autoinjector eliminates reconstitution error and contamination risk, but it also eliminates dose flexibility. The FDA-approved regimen is fixed at 1.75mg. Researchers exploring lower doses (0.5–1.0mg for different applications) or higher doses (2.5–3.0mg in male populations, though off-label) cannot adjust dosing with the branded product.
- The purity threshold is where regulatory divergence becomes tangible. FDA-approved bremelanotide must meet ≥99% purity via HPLC with defined impurity limits for each known degradation product. Research-grade PT-141 typically meets ≥97–98% purity, with the remaining 1–3% consisting of closely related peptide sequences that don't significantly alter MC4R activity. In practice, this purity difference is pharmacologically negligible for research applications. But it's the reason branded Vyleesi carries an FDA approval and PT-141 does not.